title: Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.
abstract: Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 days. Thirty patients with Gram-positive cocci BJI were included. Once the target of 25 to 40 mg/liter trough serum concentration was achieved, treatment was switched from an intravenous to an s.c. route. No discontinuation of teicoplanin related to injection site reaction and no severe local adverse event were observed. On multivariate analysis, better tolerability was observed at the beginning of treatment, in patients over 70 years old, and for dosages less than 600 mg. In conclusion, we recommend s.c. administration of teicoplanin when needed.
authors.affiliation: Department of Infectious Diseases, Amiens University Hospital, Amiens, France youssefsamad@yahoo.fr.
authors.forename: Youssef
authors.initials: Y
authors.lastname: El Samad
authors.affiliation: Department of Infectious Diseases, Amiens University Hospital, Amiens, France.
authors.forename: Jean-Philippe
authors.identifier: 0000-0003-0463-4636
authors.initials: JP
authors.lastname: Lanoix
authors.affiliation: Department of Pharmacology, Amiens University Hospital, Amiens, France.
authors.forename: Youssef
authors.initials: Y
authors.lastname: Bennis
authors.affiliation: Clinical Research and Innovation Directorate, Amiens University Hospital, Amiens, France.
authors.forename: Momar
authors.initials: M
authors.lastname: Diouf
authors.affiliation: Department of Infectious Diseases, Amiens University Hospital, Amiens, France.
authors.forename: Carlo
authors.initials: C
authors.lastname: Saroufim
authors.affiliation: Department of Orthopedic Surgery, Amiens University Hospital, Amiens, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Brunschweiler
authors.affiliation: Department of Microbiology, Amiens University Hospital, Amiens, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Rousseau
authors.affiliation: Department of Infectious Diseases, Amiens University Hospital, Amiens, France.
authors.forename: Cédric
authors.initials: C
authors.lastname: Joseph
authors.affiliation: Department of Microbiology, Amiens University Hospital, Amiens, France.
authors.forename: Farida
authors.initials: F
authors.lastname: Hamdad
authors.affiliation: Clinical Research and Innovation Directorate, Amiens University Hospital, Amiens, France.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ait Amer Meziane
authors.affiliation: Department of Pharmacology, Amiens University Hospital, Amiens, France.
authors.forename: Simon
authors.initials: S
authors.lastname: Routier
authors.affiliation: Department of Infectious Diseases, Amiens University Hospital, Amiens, France.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Schmit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood* / Q000627:therapeutic use; D001850:Bone Diseases, Infectious / Q000188:drug therapy / Q000382:microbiology; D016903:Drug Monitoring; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006095:Gram-Positive Cocci / Q000472:pathogenicity; D006801:Humans; D007279:Injections, Subcutaneous; D007592:Joint Diseases / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017334:Teicoplanin / Q000008:administration & dosage* / Q000097:blood* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin